Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil

European Journal of Clinical Pharmacology

Volumn 69, Issue 10, 2013, Pages 1809-1817

  Chen, Chao ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dose exposure relationship; Gabapentin; Gabapentin enacarbil; Meta analysis; Pharmacokinetics

Indexed keywords

GABAPENTIN; GABAPENTIN ENACARBIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, ORAL; AMINES; BIOLOGICAL AVAILABILITY; CARBAMATES; COMPUTER SIMULATION; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, BIOLOGICAL; PRODRUGS;

EID: 84884818023     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1545-1     Document Type: Article

References (47)

1. Pfizer. Neurontin US physician's prescribing information July 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=630. Accessed September 12, 2012
2. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (2008) Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 48:1378-1388
3. GlaxoSmithKline. Horizant US physician's prescribing information 2012. http://us.gsk.com/products/assets/us-horizant.pdf. Accessed September 12, 2012
4. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. doi: 10.1371/journal.pmed.1000097
5. Crombie IK, Davies HTO. What is meta-analysis? in evidence-based medicine. 2nd Ed. http://www.medicine.ox.ac.uk/bandolier/painres/download/ whatis/Meta-An.pdf. Accessed September 12, 2012
6. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2009) A disease progression meta-analysis model for cognitive deterioration in patients with Alzheimer's disease. Alzheimers Dement 5:P255
7. Li JS, Baker-Smith C, Smith PB, Hasselblad V, Murphy DM, Califf RM, Benjamin DK (2008) Racial difference in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. Clin Pharmacol Ther 84:315-319
8. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis: statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee on December 10-11, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf. Accessed September 12, 2012
9. FDA Cardiovascular and Renal Drugs Advisory Committee Meeting Briefing Document. July 29, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220250.pdf. Accessed September 12, 2012
10. FDA Drug Safety communication: Safety review update of Abacavir and possible increased risk of heart attack. March 1, 2011. http://www.fda.gov/ Drugs/DrugSafety/ucm245164.htm#summary. Accessed September 12, 2012
11. FDA. Guidance for industry: Exposure-response relationships - study design, data analysis, and regulatory applications. 2003. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf. Accessed September 12, 2012
12. Beal SL, Sheiner LB, Boeckmann AJ, eds. (1989-2010) NONMEM Users Guides. Ellicott City, MD: ICON Development Solutions
13. Gidal BE, DeCerce J, Bockbrader HN, Gozalez J, Kruger S, Pitterle ME, Rutecki P, Ramsey RE (1998) Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 31:91-99
14. Backonja MM, Canafax DM, Cundy KC (2011) Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med 12:1198-1208
15. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, Sedman AJ (1994) Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56:154-159
16. Bockbrader HN (1995) Clinical pharmacokinetics of gabapentin. Drugs Today 31:613-619
17. Bockbrader HN, Breslin EM, Underwood BA, Posvar EL, Sedman AJ (1996) Multiple-dose dose-proportionality study of Neurontin (gabapentin) in healthy volunteers. Epilepsia 37:S159
18. Boyd RA, Turck D, Abel RB, Abel RB, Sedman AJ, Bockbrader HN (1999) Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40:474-479
19. Chen C, Cowles VE, Hou E (2010) Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol. doi: 10.1177/ 0091270010368411
20. Chen D, Lal R, Zomorodi K, Atluri H, Ho J, Luo W, Tovera J, Bonzo D, Cundy K (2012) Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther 34:351-362
21. Cho HY, Kang HA, Lee YB (2006) Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers. Int J Clin Pharmacol Ther 44:386-392
22. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G (2000) Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 91:185-191
23. FDA. Neurontin NDA Review (20-882: NEURONTIN for seizure disorders and epilepsy). October, 1998. http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/ 020882a-1.pdf. Accessed September 12, 2012
24. FDA. Neurontin NDA Review (21-397/423/424: NEURONTIN for postherpetic neuralgia). May 2002. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21- 397.pdf-Neurontin-BioPharmr.pdf. Accessed September 12, 2012
25. Fischer JH, Andrews CO, Taber JE, Hier DB, Fischer PA (1995) Multidose evaluation of gabapentin pharmacokinetics in patients with epilepsy. Epilepsia 36:S158
26. Gidal BE, Maly MM, Budde J, Lensmeyer GL, Pitterle ME, Jones JC (1996) Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res 23:71-76
27. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN (2000) Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 40:123-127
28. GlaxoSmithKline. Study RXP110882: An open-label, randomized, single dose, five-period crossover study to evaluate the relative bioavailability of different formulations of GSK1838262 in healthy volunteers. GlaxoSmithKline Clinical Study Register. http://www.gsk-clinicalstudyregister.com/result-detail. jsp?protocolId=110882&studyId=F9E9DB99-7E72-494F-92C4- 718A3537783B&compound=gabapentin+enacarbil. Accessed September 12, 2012
29. GlaxoSmithKline. Study XP057/RXP111491: A randomized, cross-over, single-dose pharmacokinetic study assessing two oral sustained release formulations of XP13512 (GSK1838262) in healthy adult subjects. GlaxoSmithKline Clinical Study Register. http://www.gsk-clinicalstudyregister.com/result-detail. jsp?protocolId=111491&studyId=BF40768C-B77D-4897-9C66- B1C06811CCBA&compound=gabapentin+enacarbil. Accessed September 12, 2012
30. GlaxoSmithKline. Study XP086/RXP111422: A phase 1, randomized, open-label, formulation comparison study of the pharmacokinetics, safety, and tolerability of XP13512 Extended Release (ER) Tablet formulations and neurontin® in healthy adult male subjects. GlaxoSmithKline Clinical Study Register. http://www.gsk-clinicalstudyregister.com/result-detail.jsp?protocolId= 111422&studyId=9397657A-73C6-47DB-A116-D131619A990A&compound= gabapentin+enacarbil. Accessed September 12, 2012.
31. Gordi T, Hou E, Kasichayanula S (2008) Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 30:909-916
32. Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ (1991) Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol 31:171-174
33. Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, Tovera J, Hurt J, Bonzo D, Lassauzet ML, Vu A, Cundy KC (2012) A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol 35:165-173
34. Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC (2009) Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 31:1776-1786
35. Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC (2010) The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. Int J Clin Pharmacol Ther 48:120-128
36. Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, Cundy KC (2010) Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol 69:498-507
37. McLean MJ (1994) Clinical pharmacokinetics of gabapentin. Neurol 44:S17-S22
38. Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR (1994) Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 35:155-161
39. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10:276-281
40. Vollmer KO, Anhut H, Thomann P, Wagner F, Jahnchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv Epileptol 17:209-211
41. Vollmer KO, Turck D, Wagner F, Jahnchen E, Anhut H, Thomann P (1989) Multiple-dose pharmacokinetics of the new anticonvulsant gabapentin. Eur J Clin Pharmacol 36:S310
42. Xenoport. Study XP072: A double-blind, placebo-controlled, ascending single dose study of XP13512 in Caucasian and Japanese healthy subjects. XenoPort/GlaxoSmithKline Internal Database
43. XenoPort. Study XP073: A double-blind, placebo-controlled, ascending multiple dose study of XP13512 in Healthy Japanese subjects. XenoPort/GlaxoSmithKline Internal Database
44. Greenland S (1994) Can meta-analysis be salvaged? Am J Epidemiol 140:783-787
45. Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E (2001) Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 47:229-241
46. Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC (2012) Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol 53:29-40
47. Lockwood PA, Cook JA, Ewy WE, Mandema JW (2003) The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. Pharm Res 20:1752-1759